Rituximab dosing in hematological malignancies: an old question, revisited

Peter N. Morcos; Axel Boehnke; Nancy Valente; Donald E. Mager

doi:10.1007/s00280-019-03818-1

Rituximab dosing in hematological malignancies: an old question, revisited

Peter N. Morcos
, Axel Boehnke
, Nancy Valente
, Donald E. Mager

Pharmaceutical Sciences

Hoffmann-La Roche Inc.
F. Hoffmann-La Roche AG
Genentech, Inc

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Rituximab is the standard of care for most B-cell malignancies. Its rapid clinical development enabled patients to receive this life-prolonging medicine sooner; however, it precluded a thorough assessment of dose selection. Extensive clinical pharmacology data collected from the recent subcutaneous development program enabled re-examination of this old question and support that the approved rituximab dosing regimens in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia appear to maximize the clinical benefit in the majority of patients.

Original language	English
Pages (from-to)	661-666
Number of pages	6
Journal	Cancer Chemotherapy and Pharmacology
Volume	84
Issue number	3
DOIs	https://doi.org/10.1007/s00280-019-03818-1
State	Published - Sep 1 2019

Keywords

Dose selection
Exposure–response
Monoclonal antibody
Rituximab

Access to Document

10.1007/s00280-019-03818-1

Cite this

@article{50b82b2498f14e2d92118be994e4ddc8,

title = "Rituximab dosing in hematological malignancies: an old question, revisited",

abstract = "Rituximab is the standard of care for most B-cell malignancies. Its rapid clinical development enabled patients to receive this life-prolonging medicine sooner; however, it precluded a thorough assessment of dose selection. Extensive clinical pharmacology data collected from the recent subcutaneous development program enabled re-examination of this old question and support that the approved rituximab dosing regimens in non-Hodgkin{\textquoteright}s lymphoma and chronic lymphocytic leukemia appear to maximize the clinical benefit in the majority of patients.",

keywords = "Dose selection, Exposure–response, Monoclonal antibody, Rituximab",

author = "Morcos, \{Peter N.\} and Axel Boehnke and Nancy Valente and Mager, \{Donald E.\}",

note = "Publisher Copyright: {\textcopyright} 2019, Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2019",

month = sep,

day = "1",

doi = "10.1007/s00280-019-03818-1",

language = "English",

volume = "84",

pages = "661--666",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "3",

}

TY - JOUR

T1 - Rituximab dosing in hematological malignancies

T2 - an old question, revisited

AU - Morcos, Peter N.

AU - Boehnke, Axel

AU - Valente, Nancy

AU - Mager, Donald E.

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Rituximab is the standard of care for most B-cell malignancies. Its rapid clinical development enabled patients to receive this life-prolonging medicine sooner; however, it precluded a thorough assessment of dose selection. Extensive clinical pharmacology data collected from the recent subcutaneous development program enabled re-examination of this old question and support that the approved rituximab dosing regimens in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia appear to maximize the clinical benefit in the majority of patients.

AB - Rituximab is the standard of care for most B-cell malignancies. Its rapid clinical development enabled patients to receive this life-prolonging medicine sooner; however, it precluded a thorough assessment of dose selection. Extensive clinical pharmacology data collected from the recent subcutaneous development program enabled re-examination of this old question and support that the approved rituximab dosing regimens in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia appear to maximize the clinical benefit in the majority of patients.

KW - Dose selection

KW - Exposure–response

KW - Monoclonal antibody

KW - Rituximab

UR - https://www.scopus.com/pages/publications/85063193979

U2 - 10.1007/s00280-019-03818-1

DO - 10.1007/s00280-019-03818-1

M3 - Article

C2 - 30899984

AN - SCOPUS:85063193979

SN - 0344-5704

VL - 84

SP - 661

EP - 666

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 3

ER -

Rituximab dosing in hematological malignancies: an old question, revisited

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this